vTv Therapeutics Inc - Ordinary Shares - Class A
VTVT
Get informed when a big investor buys or sells
+ FollowMarket Cap$337.04M
Close$
$10.56
61.1% downside
Current Fair Value
61.1% downsideOvervalued by 61.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $337.04 Million |
|---|---|
| Enterprise Value | $250.39 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.2 |
| Beta | 0.29 |
| Outstanding Shares | 12,409,316 |
Return
| Return on Equity | -6.05% |
|---|---|
| Return on Assets | -5.43% |
| Return on Invested Capital | 2.44% |
Valuation & Multiples
| P/E Ratio | -283.45 |
|---|---|
| PEG | -244.54 |
| Price to Sales | 13.58 |
| Price to Book Ratio | 4.53 |
| Enterprise Value to Revenue | -0.14 |
| Enterprise Value to EBIT | -2.56 |
| Enterprise Value to Net Income | -53 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.93
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-1.07
Average shareholder expectationRevenue Estimate
$333,330
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 12.95%▼ 4.70% |
|---|---|
| Total Invested | $60.51M▲ 2.58% |
| Investors Holding | 44▲ 9.00% |
ESG Score
No data
About vTv Therapeutics Inc
25 employees
CEO: Stephen Holcombe vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes and infla...